Satellos Bioscience Inc.
TSX:MSCL.TO · Toronto Stock Exchange
+$0.01 today
Vol 0.00M · Avg 0.02M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$25.3M +9.9% | -$28.1M -76.8% | -$15.9M -40.3% | -$11.3M +27.0% | -$15.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $4.0K -80.0% | $20.0K +185.7% | $7.0K -97.9% | $337.0K +103.4% | $165.7K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $3.2M +53.1% | $2.1M -2.6% | $2.2M +50.6% | $1.4M +48.2% | $971.5K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$1.5M -46.7% | -$1.0M -377.8% | $369.0K -62.8% | $991.0K +304.1% | -$485.6K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $66.1K +253.8% | -$43.0K +86.7% | -$323.0K -220.7% | $267.5K +497.0% | -$67.4K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 | $0 -100.0% | $726.1K +286.0% | -$390.5K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.6M -59.9% | -$982.0K -241.9% | $692.0K +35936.4% | -$1.9K +93.0% | -$27.8K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$435.8K -121.6% | $2.0M +287.9% | -$1.1M -136.9% | $2.9M -70.4% | $9.8M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$24.0M +3.9% | -$25.0M -72.2% | -$14.5M -150.8% | -$5.8M -14.9% | -$5.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$6.1K -1.7% | -$6.0K +66.7% | -$18.0K -500.0% | -$3.0K +58.6% | -$7.2K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $1.7M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$23.8M +36.3% | -$37.3M -113.1% | -$17.5M | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $14.2M -67.5% | $43.7M | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$9.6M -251.2% | $6.3M +136.1% | -$17.5M -584500.0% | -$3.0K -100.2% | $1.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 +100.0% | -$284.0K | $0 -100.0% | $186.6K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.3M -94.7% | $42.8M +31.8% | $32.5M +1069.8% | $2.8M -60.8% | $7.1M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $10.7M -43.3% | $18.9M | $0 -100.0% | $185.5K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $2.3M -95.7% | $53.5M +4.8% | $51.0M +1739.0% | $2.8M -62.8% | $7.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$890.4K -219.7% | $744.0K -35.2% | $1.1M +1611.8% | -$76.0K -5163.2% | -$1.4K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$32.2M -190.5% | $35.6M +76.7% | $20.1M +783.5% | -$2.9M -170.9% | $4.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$24.0M +3.9% | -$25.0M -72.1% | -$14.5M -150.9% | -$5.8M -14.8% | -$5.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.02M
Cybin Inc.
CYBN.NE
$157.10M
Grown Rogue International Inc.
GRIN.CN
$149.96M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Zentek Ltd.
ZEN.V
$62.38M
Sernova Corp.
TSX:SVA.TO
$53.90M
Medicenna Therapeutics Corp.
MDNA.TO
$28.87M
SEC Filings
Recent regulatory filings
No filings found.
Does MSCL.TO generate free cash flow?
Satellos Bioscience Inc. (MSCL.TO) generated -$24,015,162.00 of free cash flow in fiscal 2025.
How much operating cash flow does MSCL.TO produce?
Operating cash flow was -$24,009,060.00, before capital expenditures of $6,101.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.